Immune Thrombotic Thrombocytopenia Linked to the AstraZeneca COVID-19 Vaccine

摘要

Reports of thrombotic events following the first dose of the AstraZeneca COVID-19 vaccine recently surfaced. Now, two groups provide evidence of a new syndrome, vaccine-induced immune thrombotic thrombocytopenia (VITT).Greinacher and colleagues described 11 patients in Germany and Austria (median age, 36) who developed severe thrombotic events (primarily portal, splenic, and upper mesenteric vein thrombosis, cerebral vein thrombosis, and pulmonary emboli) with concurrent thrombocytopenia within 16 days of the first dose of vaccine.